WO2005034902A1 - Composition permettant de stimuler la production de collagene - Google Patents

Composition permettant de stimuler la production de collagene Download PDF

Info

Publication number
WO2005034902A1
WO2005034902A1 PCT/JP2004/015298 JP2004015298W WO2005034902A1 WO 2005034902 A1 WO2005034902 A1 WO 2005034902A1 JP 2004015298 W JP2004015298 W JP 2004015298W WO 2005034902 A1 WO2005034902 A1 WO 2005034902A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
collagen production
composition
related substance
promoting collagen
Prior art date
Application number
PCT/JP2004/015298
Other languages
English (en)
Japanese (ja)
Inventor
Shigeo Shinohara
Mitsuaki Kawamura
Original Assignee
Otsuka Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co., Ltd filed Critical Otsuka Pharmaceutical Co., Ltd
Priority to BRPI0415229-8A priority Critical patent/BRPI0415229A/pt
Priority to EP04792515A priority patent/EP1671618B1/fr
Priority to AU2004279248A priority patent/AU2004279248B2/en
Priority to ES04792515T priority patent/ES2376062T3/es
Priority to AT04792515T priority patent/ATE536167T1/de
Priority to JP2005514663A priority patent/JP4614886B2/ja
Priority to US10/574,696 priority patent/US7557093B2/en
Priority to CA2541584A priority patent/CA2541584C/fr
Publication of WO2005034902A1 publication Critical patent/WO2005034902A1/fr
Priority to HK06114104.8A priority patent/HK1093891A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q3/00—Manicure or pedicure preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Definitions

  • the present invention relates to a composition for promoting collagen production. Furthermore, the present invention relates to a method for promoting collagen production in the skin dermis.
  • Collagen is a component that occupies about 90% of the dermis of the skin and plays a role in supporting the skin structure, providing a living environment for cells, and retaining water. Collagen is known to be lost due to specific extrinsic effects on the skin due to exposure to ultraviolet light and drying. It is also known that collagen is lost by aging and stress. Exogenous effects and aging have also been shown to cause a decrease in collagen production by fibroblasts.
  • an object of the present invention is to provide a composition for promoting collagen production, which can promote collagen production, particularly collagen production in human skin dermis.
  • Another object of the present invention is to provide the above-mentioned composition for promoting collagen production which is used as an external preparation.
  • the present inventors have conducted intensive studies to solve the above-mentioned problems, and found that purine nucleic acid-related substances, particularly adenosine 5'-monophosphate or a salt thereof, have an action of promoting the production of collagen in skin dermis. I found that. Also, pyrimidine nucleic acid-related substances The quality was found to have the effect of enhancing the action of purine nucleic acid-related substances to promote collagen production. The present invention has been further developed based on such knowledge.
  • compositions for promoting collagen production Item 1.
  • a composition for promoting collagen production comprising a purine nucleic acid-related substance.
  • Item 2 The composition for promoting collagen production according to Item 1, further comprising a pyrimidine nucleic acid-related substance.
  • the purine nucleic acid-related substance is at least one selected from the group consisting of adenine, adenosine, adenosine phosphate ester, adenosine phosphate ester metabolite, and salts thereof.
  • the composition for promoting collagen production according to 1. Item 4. The composition for promoting collagen production according to Item 1, wherein the purine nucleic acid-related substance is at least one selected from the group consisting of adenosine monophosphate and a salt thereof.
  • Item 5 The composition for promoting collagen production according to Item 1, wherein the purine nucleic acid-related substance is at least one member selected from the group consisting of adenosine 5'-phosphate and salts thereof.
  • Item 6 The composition for promoting collagen production according to Item 2, wherein the pyrimidine nucleic acid-related substance is at least one selected from the group consisting of peracyl, peridine, phosphate esters of peridine, and salts thereof.
  • Item 7 The composition for promoting collagen production according to Item 2, wherein the pyrimidine nucleic acid-related substance is at least one member selected from the group consisting of peridine monophosphate and a salt thereof.
  • Item 8 The composition for promoting collagen production according to Item 2, wherein the pyrimidine nucleic acid-related substance is at least one member selected from the group consisting of peridine 5'-monophosphate and a salt thereof.
  • the purine nucleic acid-related substance is at least one selected from the group consisting of adenine, adenosine, adenosine phosphate ester, adenosine phosphate ester metabolite, and salts thereof, and pyrimidine.
  • Item 3. The composition for promoting collagen production according to Item 2, wherein the nucleic acid-related substance is at least one selected from the group consisting of peracyl, peridine, phosphate esters of peridine, and salts thereof.
  • Item 10 The purine nucleic acid-related substance is selected from the group consisting of adenosine monophosphate and salts thereof.
  • Item 3. The composition according to Item 2, wherein the pyrimidine nucleic acid-related substance is at least one selected from the group consisting of peridine monophosphate and a salt thereof.
  • the purine nucleic acid-related substance is at least one member selected from the group consisting of adenosine 5'-phosphate and a salt thereof, and the pyrimidine nucleic acid-related substance is peridine 5'-monophosphate and a salt thereof.
  • Item 3 The composition for promoting collagen production according to Item 2, which is at least one selected from the group.
  • composition for promoting collagen production according to Item 2 comprising a pyrimidine nucleic acid-related substance in a proportion of 0.001 to 100 parts by weight based on 1 part by weight of the purine nucleic acid-related substance.
  • Item 13 The composition for promoting collagen production according to Item 1, wherein the purine nucleic acid-related substance is contained in a proportion of 0.01 to 10% by weight based on the total amount of the composition for promoting collagen production.
  • Item 14 The composition for promoting collagen production according to Item 1, wherein the pyrimidine nucleic acid-related substance is contained in a ratio of 0.0001 to 10% by weight based on the total amount of the composition for promoting collagen production.
  • Item 15 The composition for promoting collagen production according to Item 1, which is a cosmetic, an external medicine, or a quasi-drug.
  • Item 16 The composition for promoting collagen production according to Item 1, which is a cosmetic.
  • the present invention also provides a method for promoting the production of collagen described below:
  • Item 17 A method for promoting collagen production, comprising applying a purine nucleic acid-related substance to skin.
  • Item 18 The method for promoting collagen production according to Item 17, characterized in that a pyrimidine nucleic acid-related substance is applied to the skin together with the purine nucleic acid-related substance.
  • Item 19 The method for promoting collagen production according to Item 17, wherein an external composition containing a purine nucleic acid-related substance is applied to skin.
  • Item 20 The method for promoting collagen production according to Item 18, wherein an external composition containing a purine nucleic acid-related substance and a pyrimidine nucleic acid-related substance is applied to skin.
  • Purine nucleic acid-related substance is adenine, adenosine, adenosine phosphate Item 18.
  • Item 22 The method for promoting collagen production according to Item 17, wherein the purine nucleic acid-related substance is at least one selected from the group consisting of adenosine monophosphate and salts thereof.
  • Item 23 The method for promoting collagen production according to Item 17, wherein the purine nucleic acid-related substance is at least one selected from the group consisting of adenosine 5'-monophosphate and salts thereof.
  • Item 24 The method for promoting collagen production according to Item 18, wherein the pyrimidine nucleic acid-related substance is at least one selected from the group consisting of peracyl, peridine, phosphate esters of peridine, and salts thereof.
  • Item 25 The method for promoting collagen production according to Item 18, wherein the pyrimidine nucleic acid-related substance is at least one selected from the group consisting of peridine monophosphate and salts thereof.
  • Item 26 The method for promoting collagen production according to Item 18, wherein the pyrimidine nucleic acid-related substance is at least one member selected from the group consisting of peridine 5'-phosphate and salts thereof.
  • the purine nucleic acid-related substance is at least one selected from the group consisting of adenine, adenosine, adenosine phosphate, metabolite of adenosine phosphate, and salts thereof, and a pyrimidine nucleic acid.
  • Item 18 The method for promoting collagen production according to Item 18, wherein the related substance is at least one selected from the group consisting of peracil, peridine, a phosphate ester of peridine, and a salt thereof.
  • the purine nucleic acid-related substance is at least one selected from the group consisting of adenosine monophosphate and salts thereof, and the pyrimidine nucleic acid-related substance is selected from the group consisting of peridine monophosphate and salts thereof.
  • Item 18 The method for promoting collagen production according to Item 18, which is at least one kind.
  • the purine nucleic acid-related substance is at least one member selected from the group consisting of adenosine 5'-monophosphate and a salt thereof, and the pyrimidine nucleic acid-related substance is a substance derived from peridine 5'-monophosphate and a salt thereof. At least one member selected from the group consisting of: 19. The method for promoting collagen production according to 18.
  • Item 30 The method for promoting collagen production according to Item 18, wherein the pyrimidine nucleic acid-related substance is contained in a proportion of 0.001 to 100 parts by weight based on 1 part by weight of the purine nucleic acid-related substance.
  • Item 31 The method for promoting collagen production according to Item 19, wherein the purine nucleic acid-related substance is contained in a ratio of 0.01 to 10% by weight based on the total amount of the composition for external use.
  • the pyrimidine nucleic acid-related substance is 0.001 to 0.001 to the total amount of the composition.
  • Item 21 The method for promoting collagen production according to Item 20, which is contained at a ratio of 10% by weight.
  • Item 34 The method for promoting collagen production according to Item 19, wherein the composition for external use is a cosmetic.
  • Item 35 The method for promoting collagen production according to Item 1, wherein the composition for promoting collagen production according to Item 1 is applied to skin.
  • Item 36 The method for promoting collagen production according to Item 18, wherein the composition for promoting collagen production according to Item 2 is applied to skin.
  • Item 37 Use of a purine nucleic acid-related substance for producing a composition for promoting collagen production.
  • Item 38 Use of a purine-based diffusion-related substance and a pyrimidine-based nucleic acid-related substance for production of a composition for promoting collagen production.
  • Item 39 Use of a purine nucleic acid-related substance for producing collagen.
  • Item 40 Use of a purine-based diffusion-related substance and a pyrimidine-based nucleic acid-related substance for producing collagen. Brief Description of Drawings
  • FIG. 1 is a graph showing the concentration of PICP produced in Test Example 1 when human dermal fibroblasts were cultured in media containing various concentrations of AMP2Na.
  • Figure 2 shows the concentration of PICP produced when human skin 13 ⁇ 4 fibroblasts were cultured in media containing various concentrations of AMP2Na and UMP2Na in Test Example 2. is there. BEST MODE FOR CARRYING OUT THE INVENTION
  • the composition for promoting collagen production of the present invention is characterized by containing a purine nucleic acid-related substance as an active ingredient.
  • the purine nucleic acid-related substances include various derivatives having a purine or purine nucleus skeleton and salts thereof.
  • the purine nucleic acid-related substance used in the present invention is not particularly limited as long as it can be incorporated into cosmetics, external medicines or quasi-drugs. Preferably, they are water-soluble or hydrophilic.
  • Purine nucleic acid-related substances generally include adenine, adenosine, adenosine phosphate (eg, adenosine 2'-phosphate, adenosine 3'-phosphate, adenosine 5'-phosphate, adenosine 5'-diphosphate, Adenosine 5, monotriphosphate, adenosine cyclic phosphate, adenylosuccinic acid, nicotinamide adenine monodinucleotide (NMN), nicotinamide adenine dinucleotide (NA D :), nicotinamide adenine dinucleotide phosphate (NAD P) , Flavin adenine dinucleo
  • the purine nucleic acid-related substance include the adenine nucleic acid-related substances listed above. More preferred are adenosine phosphates, their metabolites and their salts, and even more preferred are adenosine phosphates and their salts. Among the phosphate esters of adenosine, adenosine 2'-phosphate, adenosine 3'-phosphate, adenosine 5'-phosphate, and other adenosine-phosphate, particularly adenosine 5'-, are preferably used. Phosphoric acid (AMP) can be mentioned.
  • AMP Phosphoric acid
  • the above-mentioned salts include alkali metal salts such as sodium salts and potassium salts; Alkaline earth metal salts such as calcium salt, magnesium salt and barium salt; basic amino acid salts such as arginine and lysine; ammonium salts such as ammonium salt and tricyclohexyl ammonium salt; monoethanolamine salt, diethanolamine salt and triethanolamine salt Examples include various alcohol salts such as ethanolamine salts, monoisopropanolamine salts, diisopropanolamine; ⁇ and triisopropanolamine.
  • alkali metal salts such as sodium salts. Specific examples of such alkali metal salts include sodium adenosine monophosphate and sodium adenosine-phosphate.
  • purine nucleic acid-related products may be used singly as an active ingredient of the composition for promoting collagen production of the present invention, or may be used in any combination of two or more. Is also good.
  • the percentage of the purine nucleic acid-related substance to be added to the composition for promoting collagen production of the present invention includes the type of the purine nucleic acid-related substance, the presence or absence and the type of the pyrimidine nucleic acid-related substance described below, although it varies depending on the form and the like, it can be appropriately selected and adjusted usually from the range of 0.01 to 10% by weight based on the total weight of the composition. Preferably «: 1 to 10% by weight, more preferably 3 to 6% by weight.
  • the composition for promoting collagen production of the present invention preferably contains a pyrimidine nucleic acid-related substance in addition to the purine nucleic acid-related substance. The production promoting action can be further enhanced.
  • the pyrimidine nucleic acid-related substances are pyrimidine or various derivatives having a pyrimidine nucleus as a skeleton and salts thereof.
  • the pyrimidine-based nucleic acid-related substance to be added to the composition for promoting collagen production of the present invention is not particularly limited as long as it can be used for cosmetics, external medicines or quasi-drugs.
  • Preferred pyrimidine-based nucleic acid-related substances include water-soluble or hydrophilic substances.
  • Specific examples of such pyrimidine nucleic acid-related substances include peracyl, peridine, peridine phosphate [peridine monophosphate (peridine 5'-phosphate, peridine 3'-phosphate, peridine 2'-phosphate).
  • Lysine diphosphate Lysine triphosphate, lysine cyclic phosphate, etc.
  • deoxyperidine phosphate ester of deoxyperidine [5'-deoxyperidine diphosphate (dUDP), 5'-deoxy) Lysic acid (dUMP) etc.] and peracile nucleic acid-related substances such as salts thereof; phosphine, cytidine, cytidine phosphate (CMP) [cytidine monophosphate (cytidine 5'-phosphate, cytidine 3'-phosphate Acid, cytidine 2'-phosphate), cytidine diphosphate (CTP), cytidine diphosphate (CDP)], deoxycytidine, phosphoric acid ester of deoxycytidine (5'_dexoxycytidine triphosphate (dCTP), 5 ' -Doxycytidinyl diphosphate (dCDP), 5'-deoxycyt
  • the purity (purity) thereof is not particularly limited.
  • a plant extract containing the above-mentioned components such as a cruciferous plant (particularly, a seed) or a leguminous plant extract may be used.
  • the peracyl nucleic acid-related substances listed above are pyrimidine-based nucleic acid-related substances that are preferably used because the collagen production activity of the purine nucleic acid-related substances can be more effectively enhanced.
  • preferred is peridine, perisine phosphate or a salt thereof, and more preferred is peridine phosphate or a salt thereof.
  • preferred are peridine monophosphate, particularly peridine 5'-phosphate (UMP).
  • Examples of the above-mentioned salts include: alkaline metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as canodium salt, magnesium salt and barium salt; basic amino acid salts such as arginine and lysine; Ammonia salts such as ammonium salts and tricyclohexyl ammonium salts; various alcohols such as monoethanolamine salts, diethanolamine salts, triethanolamine salts, monoisopropanolamine salts, diisopropanolanolamine salts and triisopropanolamine. Salts and the like can be mentioned.
  • alkali metal salts such as sodium salts are preferred.
  • Specific examples of such alkali metal salts include monosodium peridine monophosphate, An example is sodium phosphate monophosphate.
  • pyrimidine nucleic acid-related substances may be used alone or in combination of two or more in the composition for promoting collagen production of the present invention.
  • the proportion of the pyrimidine nucleic acid-related substance to be added to the composition for promoting collagen production of the present invention is not particularly limited as long as the effect of enhancing the collagen production promotion is exerted.
  • 1 part by weight of the purine nucleic acid-related substance is used.
  • the pyrimidine nucleic acid-related substance can be appropriately selected from the range of 0.001 to 100 parts by weight.
  • the pyrimidine-based nucleic acid-related substance is contained in an amount of 0.01 to 100 parts by weight, more preferably 0.01 to 10 parts by weight, more preferably 0.01 to 100 parts by weight, based on 1 part by weight of the purine-based nucleic acid-related substance. 0.0 1 to 1 part by weight.
  • the ratio of the pyrimidine-based nucleic acid-related substance to the total weight of the composition for promoting collagen production is, for example, 0.0001 to 10% by weight, preferably 0.00% by weight of the pyrimidine-based nucleic acid-related substance in total. 0.1 to 1% by weight, more preferably 0.001 to 0.1% by weight.
  • composition for promoting collagen production of the present invention is prepared in various forms by combining a pharmaceutically or cosmetically acceptable base or carrier in addition to the above components.
  • a pharmaceutically or cosmetically acceptable base and carrier conventionally known bases and carriers can be used.
  • the composition for promoting collagen production of the present invention may contain, if necessary, various known components to be added to the composition for external use applied to skin or mucous membranes such as cosmetics, external medicines and quasi-drugs. Can be blended.
  • Such components include, for example, surfactants, pigments (dyes and pigments), fragrances, preservatives, bactericides (antimicrobial agents), thickeners, antioxidants, metal sealants,, fresheners, deodorants Agents, moisturizers, UV absorbers, UV scattering agents, vitamins, plant extracts, skin astringents, anti-inflammatory agents (anti-inflammatory agents), whitening agents, cell activators, vasodilators, blood circulation enhancers, and skin functions Enhancers and the like.
  • surfactants for example, surfactants, pigments (dyes and pigments), fragrances, preservatives, bactericides (antimicrobial agents), thickeners, antioxidants, metal sealants,, fresheners, deodorants Agents, moisturizers, UV absorbers, UV scattering agents, vitamins, plant extracts, skin astringents, anti-inflammatory agents (anti-inflammatory agents), whitening agents, cell activators, vasodilators, blood circulation enhancers, and skin functions Enhancers and the like.
  • the surfactant include higher fatty acid soap, alkyl sulfate ester salt, polyoxyethylene alkyl ether sulfate salt, alkyl ether phosphate ester salt, N-acyl amino acid salt, and acyl N- Anionic surfactants such as methyltaurine salt; a freshener; a cationic surfactant such as alkyltrimethylammonium chloride and dialkyldimethylammonium chloride; alkyldimethylaminoacetic acid solid Amphoteric surfactants such as betaine, alkylamidodimethylaminoacetate betaine, 2-alkyl-1-N-carboxy N-hydroxyimidazolinidum betaine; polyoxyethylene type, polyhydric alcohol ester type, ethylene oxide propylene oxide Nonionic surfactants such as oxide block copolymers can be used. Further, there is no particular limitation, and a surfactant belonging to a polymer surfactant or a
  • preservative examples include ethyl ethyl paraoxybenzoate, salicylic acid, and sorbic acid.
  • thickener examples include xanthan gum, sodium carboxymethylcellulose, and lipoxyvinyl polymer.
  • metal sequestering agent examples include sodium salt of ethylenediaminetetraacetic acid, phosphoric acid, and citric acid.
  • the composition for promoting collagen production of the present invention is used as an external composition to be applied or sprayed on the skin. More specifically, the composition for promoting collagen production of the present invention is used as an external preparation (external coating) for cosmetics, external medicines or quasi-drugs. Of these, cosmetics are preferred from the viewpoint that collagen production by the skin can be promoted on a daily basis.
  • Such external preparations include various hair cosmetics such as hair restorer and hair restorer, or shampoos, rinses, hair lotions (including tonics and liquids) that are effective in hair restorer and hair restorer.
  • the form of the collagen production-promoting composition of the present invention is not particularly limited as long as it can be applied to skin and mucous membranes, and examples thereof include a paste, a mousse, a jewel, a liquid, an emulsion, and a suspension.
  • examples include a suspension, a cream, an ointment, a sheet, an aerosol, a spray, and a liniment.
  • emulsions such as emollient emulsion, milky lotion, nourishing emulsion and cleansing emulsion
  • creams such as emollient cream, mass cream, cleansing cream, makeup cream, etc. can do.
  • a hair product such as a hair restorer or a hair restorer
  • tonics hair creams, hair lotions, aerosols (sprays), mousses, shampoos, rinses, and liquids
  • hair creams hair lotions
  • hair lotions hair lotions
  • aerosols sprays
  • mousses shampoos
  • rinses rinses
  • liquids liquids
  • the composition for promoting collagen production of the present invention may be a cosmetic, an external medicine, or an external medicine department.
  • an external product it can be used by directly applying, spraying or affixing it to the skin or mucous membranes.
  • the effective amount to promote collagen production should be changed from once / day to 5 or 6 times / day, depending on the age of the user (human). Is administered transdermally to the skin.
  • composition for promoting collagen production of the present invention promotes the production of collagen, thereby providing anti-aging, moisturizing, anti-acne, anti-shi, anti-sag, anti-dullness, hair growth, anti-dandruff, beautiful nails, wound treatment, etc.
  • the composition for promoting collagen production of the present invention can be used for the purpose of anti-aging, moisturizing, anti-acne, anti-skin, anti-sag, pile dullness, hair growth, anti-dandruff, anti-dandruff, beauty nail, wound treatment, etc. It can be used as pharmaceuticals or quasi-drugs for external use.
  • the composition for promoting collagen production of the present invention is useful as various external preparations for the purpose of anti-aging, moisturizing, anti-acne, anti-shiga, anti-sag, anti-dullness, hair growth, beautiful nails, and wound treatment. is there.
  • the composition for promoting collagen production of the present invention can effectively exert an anti-cytosis effect, and is therefore useful as various external preparations for anti-cytosis.
  • the composition for promoting collagen production of the present invention exerts an excellent collagen production promoting effect when applied to skin. Accordingly, the present invention further provides a use of a purine nucleic acid-related substance for producing a composition for promoting collagen production; and a use of a purine nucleic acid-related substance and a pyrimidine nucleic acid-related substance for promoting collagen production. Provides use for manufacturing.
  • the present invention also provides a method for promoting collagen production.
  • the method is performed by applying a purine nucleic acid-related substance to the skin.
  • the above-mentioned substance can be conveniently applied to the skin by applying, spraying or sticking the composition for promoting collagen production of the above (I) on the skin.
  • the frequency and amount of applying the purine nucleic acid-related substance or the purine nucleic acid-related substance and the pyrimidine nucleic acid-related substance to the skin are not particularly limited. For example, depending on the age, gender, expected effect, degree of skin symptoms, etc. of the subject, an appropriate amount can be applied transdermally to the skin from once a day to 5 or 6 times a day. You.
  • the application ratio of the composition to the area of the applied skin is 0.5%.
  • An amount such that it is in the range of ⁇ 1 Omg / cm 2 can be used as a guide of the amount applied once.
  • wZv% means the weight (g) contained in 100 ml.
  • a lotion having the above formulation was prepared according to a conventional method.
  • Emulsion of the above formulation was prepared according to a conventional method.
  • Adenosine-ninadium phosphate 10.0 (% by weight) Peridine-disodium phosphate 1.0
  • a hair restorer having the above formulation was prepared according to a conventional method.
  • Test Example 1 Evaluation of collagenase-promoting effect of adenosine-ninadium phosphate on cultured human dermal fibroblasts
  • AMP 2Na adenosine monosodium monophosphate
  • PICP Procollagen type IC-peptide
  • UMP2Na Collagen production promoting effect exerted by the combined use of AMP 2Na and disodium peridine monophosphate (hereinafter referred to as UMP2Na) was evaluated. Specifically, a medium (test medium 1 to 4) containing AMP2Na and UMP2Na at the ratios shown in Table 1 below was prepared, and except that these were used, the same as in Test Example 1 above was used. The method was used to evaluate the effect of cultured human dermal fibroblasts on collagen production. In Table 1, AMP 2Na and UMP 2Na were converted to AMP and UMP concentrations, respectively. table 1
  • Fig. 2 shows the obtained results. From Fig. 2, it can be seen that AMP 2 Na has a collagen production promoting effect, and that UMP 2Na itself does not have a collagen production promoting effect, but that AMP 2 Na has a markedly enhanced collagen production promoting effect. Obvious and became. Industrial applicability
  • the purine nucleic acid-related substance which is an active ingredient of the composition for promoting collagen production of the present invention, has an excellent collagen production promoting action.
  • the collagen production promoting action of the purine nucleic acid-related substance is significantly enhanced by the presence of the pyrimidine nucleic acid-related substance. Therefore, the composition for promoting collagen production of the present invention can be used as a collagen production promoter, and can effectively promote the production of collagen, particularly the production of collagen in skin dermis.
  • the present invention has an excellent collagen production promoting action, and is useful for anti-aging, moisturizing, anti-acne, anti-shi, anti-sag, pile dullness, hair growth, anti-dandruff, beautiful nail, wound treatment, etc. External preparation can be provided.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne une composition permettant de stimuler la production de collagène et plus particulièrement la production de collagène dans le derme humain. L'invention concerne également une méthode permettant de stimuler la production de collagène. L'invention concerne plus précisément une composition permettant de stimuler la production de collagène contenant, comme ingrédient actif, une substance associée à l'acide nucléique du type de la purine ; une composition permettant de stimuler la production de collagène contenant une substance associée à l'acide nucléique du type de la purine et une substance associée à l'acide nucléique du type de la pyrimidine ; et une méthode permettant de stimuler la production de collagène, se caractérisant par le fait qu'elle consiste à appliquer sur la peau une substance associée à l'acide nucléique du type de la purine ou un mélange d'une substance associée à l'acide nucléique du type de la purine et d'une substance associée à l'acide nucléique du type de la pyrimidine.
PCT/JP2004/015298 2003-10-08 2004-10-08 Composition permettant de stimuler la production de collagene WO2005034902A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BRPI0415229-8A BRPI0415229A (pt) 2003-10-08 2004-10-08 composição para promoção de produção de colágeno
EP04792515A EP1671618B1 (fr) 2003-10-08 2004-10-08 Composition permettant de stimuler la production de collagene
AU2004279248A AU2004279248B2 (en) 2003-10-08 2004-10-08 Composition for promoting collagen production
ES04792515T ES2376062T3 (es) 2003-10-08 2004-10-08 Composición para estimular la producción de col�?geno.
AT04792515T ATE536167T1 (de) 2003-10-08 2004-10-08 Zusammensetzung zur förderung der kollagenproduktion
JP2005514663A JP4614886B2 (ja) 2003-10-08 2004-10-08 コラーゲン産生促進用組成物
US10/574,696 US7557093B2 (en) 2003-10-08 2004-10-08 Composition for promoting collagen production
CA2541584A CA2541584C (fr) 2003-10-08 2004-10-08 Composition stimulant la production de collagene comportant une substance associee aux purines de l'acide nucleique et une substance associee aux pyrimidine de l'acide nucleique
HK06114104.8A HK1093891A1 (en) 2003-10-08 2006-12-22 Composition for promoting collagen production

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003-349156 2003-10-08
JP2003349156 2003-10-08

Publications (1)

Publication Number Publication Date
WO2005034902A1 true WO2005034902A1 (fr) 2005-04-21

Family

ID=34430996

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/015298 WO2005034902A1 (fr) 2003-10-08 2004-10-08 Composition permettant de stimuler la production de collagene

Country Status (13)

Country Link
US (1) US7557093B2 (fr)
EP (1) EP1671618B1 (fr)
JP (2) JP4614886B2 (fr)
KR (1) KR20060132817A (fr)
CN (1) CN100569213C (fr)
AT (1) ATE536167T1 (fr)
AU (1) AU2004279248B2 (fr)
BR (1) BRPI0415229A (fr)
CA (1) CA2541584C (fr)
ES (1) ES2376062T3 (fr)
HK (1) HK1093891A1 (fr)
TW (1) TW200514575A (fr)
WO (1) WO2005034902A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006225271A (ja) * 2005-02-15 2006-08-31 Otsuka Pharmaceut Co Ltd シワの予防又は改善剤
KR100903654B1 (ko) 2007-10-10 2009-06-18 (주)더페이스샵코리아 하고초 추출물과 아데노신을 함유하는 화장료 조성물
WO2011162416A1 (fr) 2010-06-25 2011-12-29 Otsuka Pharmaceutical Co., Ltd. Agent inhibant la formation de cellules cutanées anormales induite par l'exposition à la lumière
WO2012105542A1 (fr) 2011-02-01 2012-08-09 株式会社林原生物化学研究所 Préparation externe pour la peau
JP2014088329A (ja) * 2012-10-29 2014-05-15 Picaso Cosmetic Laboratory Ltd 美容用組成物
WO2019021988A1 (fr) 2017-07-24 2019-01-31 大塚製薬株式会社 Composition topique
US10966983B2 (en) 2008-06-09 2021-04-06 Otsuka Pharmaceutical Co., Ltd. Composition for external use

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101778619B (zh) * 2007-08-06 2012-05-23 大塚制药株式会社 含有腺嘌呤化合物的凝胶状外用组合物
CN103347505B (zh) 2011-02-14 2015-02-04 J-制油株式会社 皮肤胶原蛋白增强剂
JP2013193985A (ja) * 2012-03-19 2013-09-30 Kao Corp 育毛剤
JP2014141475A (ja) * 2012-12-27 2014-08-07 Daiichi Sankyo Co Ltd 新規美白剤
KR101507224B1 (ko) * 2013-05-29 2015-03-30 부산대학교 산학협력단 마늘 유래 우라실을 유효성분으로 함유하는 주름 개선용 조성물
US9937119B2 (en) 2013-10-29 2018-04-10 Mary Kay Inc. Cosmetic compositions
US11219632B2 (en) 2017-02-08 2022-01-11 Oriental Yeast Co., Ltd. Skin pigmentation inhibitor
KR102026365B1 (ko) * 2018-05-11 2019-11-04 주식회사 네이처인랩 우리딘 및 활성촉진 복합체를 포함하는 화장료 조성물
WO2023058731A1 (fr) 2021-10-07 2023-04-13 ヤマサ醤油株式会社 Composition de soin de la peau et son utilisation, et matériau de source de composition de soin de la peau

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63183535A (ja) * 1986-09-18 1988-07-28 Lion Corp 皮膚外用剤
JPH0648934A (ja) * 1992-06-02 1994-02-22 Sansho Seiyaku Co Ltd 皮膚外用剤
JPH09295915A (ja) * 1996-04-26 1997-11-18 Kikkoman Corp 皮膚化粧料
JP2001031549A (ja) * 1999-07-14 2001-02-06 Pola Chem Ind Inc 真皮コラーゲン線維束再構築剤及びそれを含有する化粧料
JP2003040729A (ja) * 2001-07-04 2003-02-13 Basf Ag 皮膚化粧用組成物における５’−デオキシ−５’−メチルチオアデノシンの使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4266855A (en) 1979-09-24 1981-05-12 Quantor Corporation Quick change lens system
ES507187A0 (es) * 1981-11-16 1983-01-01 Union Ind Y Agro Ganader S A U Procedimiento de obtencion de una leche humanizada adiciona-da de nucleotidos con destino a la alimentacion infantil.
ES526873A0 (es) * 1982-10-27 1985-04-16 Crinos Industria Farmaco Procedimiento de obtencion de composiciones para promover el trofismo de la piel y de foliculos piliferosos relacionados
EP0256472A3 (fr) 1986-08-11 1988-09-07 Lion Corporation Agent cosmétique pour application sur la peau
US5182269A (en) * 1987-09-23 1993-01-26 Crinos Industria Farmacobiologica Spa Composition for topical use having hair stimulating, anti-dandruff and anti-seborrhoic activity
JPH07233037A (ja) * 1993-12-29 1995-09-05 Sansho Seiyaku Co Ltd 皮膚化粧料
US5602109A (en) * 1994-01-10 1997-02-11 Abbott Laboratories Method to enhance the immune system of a human
GB9701374D0 (en) 1997-01-23 1997-03-12 Univ Liverpool Purinergic agonists and antagonists
US6203805B1 (en) * 1998-11-10 2001-03-20 Color Access, Inc. Topical compositions containing whey proteins
JP2001278783A (ja) 2000-03-29 2001-10-10 Shiseido Co Ltd コラーゲン産生促進剤
JP3608078B2 (ja) 2000-05-11 2005-01-05 株式会社アルソア本社 コラーゲン産生促進剤、エストロゲン様作用剤、皮膚化粧料および美容食品
US6759033B2 (en) * 2000-06-22 2004-07-06 Access Business Group International Llc Method for slowing the decomposition of a cosmetic composition
AU2002238988B2 (en) * 2001-04-13 2006-11-16 Otsuka Pharmaceutical Co., Ltd. Sugar intake promoters
JP4627988B2 (ja) * 2002-04-09 2011-02-09 大塚製薬株式会社 細胞増殖用組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63183535A (ja) * 1986-09-18 1988-07-28 Lion Corp 皮膚外用剤
JPH0648934A (ja) * 1992-06-02 1994-02-22 Sansho Seiyaku Co Ltd 皮膚外用剤
JPH09295915A (ja) * 1996-04-26 1997-11-18 Kikkoman Corp 皮膚化粧料
JP2001031549A (ja) * 1999-07-14 2001-02-06 Pola Chem Ind Inc 真皮コラーゲン線維束再構築剤及びそれを含有する化粧料
JP2003040729A (ja) * 2001-07-04 2003-02-13 Basf Ag 皮膚化粧用組成物における５’−デオキシ−５’−メチルチオアデノシンの使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CROUCHER L.J. ET AL.: "Extracellular ATP and UTP stimulate cartilage proteoglycan and collagen accumulation in bovine articular chondrocyte pellet cultures", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1502, 2000, pages 297 - 306, XP004277011 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006225271A (ja) * 2005-02-15 2006-08-31 Otsuka Pharmaceut Co Ltd シワの予防又は改善剤
KR100903654B1 (ko) 2007-10-10 2009-06-18 (주)더페이스샵코리아 하고초 추출물과 아데노신을 함유하는 화장료 조성물
US10966983B2 (en) 2008-06-09 2021-04-06 Otsuka Pharmaceutical Co., Ltd. Composition for external use
WO2011162416A1 (fr) 2010-06-25 2011-12-29 Otsuka Pharmaceutical Co., Ltd. Agent inhibant la formation de cellules cutanées anormales induite par l'exposition à la lumière
US9125928B2 (en) 2010-06-25 2015-09-08 Otsuka Pharmaceutical Co., Ltd. Agent for suppressing the formation of abnormal skin cells caused by exposure to light
WO2012105542A1 (fr) 2011-02-01 2012-08-09 株式会社林原生物化学研究所 Préparation externe pour la peau
US9492368B2 (en) 2011-02-01 2016-11-15 Hayashibara Co., Ltd. External preparation for skin
JP2014088329A (ja) * 2012-10-29 2014-05-15 Picaso Cosmetic Laboratory Ltd 美容用組成物
WO2019021988A1 (fr) 2017-07-24 2019-01-31 大塚製薬株式会社 Composition topique

Also Published As

Publication number Publication date
CN1867316A (zh) 2006-11-22
CA2541584A1 (fr) 2005-04-21
JP2010215648A (ja) 2010-09-30
AU2004279248A1 (en) 2005-04-21
US20070135374A1 (en) 2007-06-14
KR20060132817A (ko) 2006-12-22
JP4614886B2 (ja) 2011-01-19
EP1671618A4 (fr) 2009-11-11
TW200514575A (en) 2005-05-01
JPWO2005034902A1 (ja) 2006-12-21
TWI347846B (fr) 2011-09-01
ATE536167T1 (de) 2011-12-15
US7557093B2 (en) 2009-07-07
CN100569213C (zh) 2009-12-16
BRPI0415229A (pt) 2006-12-05
EP1671618B1 (fr) 2011-12-07
HK1093891A1 (en) 2007-03-16
ES2376062T3 (es) 2012-03-08
CA2541584C (fr) 2013-02-26
AU2004279248B2 (en) 2011-05-12
EP1671618A1 (fr) 2006-06-21

Similar Documents

Publication Publication Date Title
JP2010215648A (ja) コラーゲン産生促進用組成物
AU2003220857B2 (en) Composition for cell proliferation
JP7300988B2 (ja) 外用組成物
EP1547577B1 (fr) Composition antivieillisement
JP5546253B2 (ja) 外用組成物
JP2006225271A (ja) シワの予防又は改善剤
WO2023191016A1 (fr) Promoteur de production de fibrilline, composition cosmétique ou agent topique pour la peau, agent à administrer par voie orale et promoteur de production de fibres d'élastine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480029737.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 12006500589

Country of ref document: PH

Ref document number: 2004279248

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1671/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005514663

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2541584

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004792515

Country of ref document: EP

Ref document number: 1020067006844

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004279248

Country of ref document: AU

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWP Wipo information: published in national office

Ref document number: 2004792515

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007135374

Country of ref document: US

Ref document number: 10574696

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0415229

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 1020067006844

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 10574696

Country of ref document: US